Xilio Therapeutics Inc (XLO) - News Archive

Showing 9 of 9 results.

Xilio Therapeutics Empowers Growth with New Stock Options Amidst Record Price Performance,

Xilio Therapeutics Empowers Growth with New Stock Options Amidst Record Price Performance In a notable move for its workforce and operational strategy, Xilio Therapeutics, Inc. (Nasdaq: XLO) announced on February 3, 202...

Feb 3, 2025 • Major Pharmaceutical Preparations Industry Stock Market Announcement

Xilio Therapeutics Reinforces Growth Strategy with New Stock Options Amid Promising Clinical Advances

WALTHAM, Mass. In a notable move to bolster its talent pool and ensure alignment with the company s ambitious growth strategies, Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology firm dedicated to d...

Jan 17, 2025 • Major Pharmaceutical Preparations Industry Shares

Xilio Therapeutics Boosts Leadership and Growth Potential with Strategic Stock Option Plan

WALTHAM, Mass. In a decisive move to fortify its executive leadership and continue its pioneering journey in immuno-oncology, Xilio Therapeutics, Inc. (Nasdaq: XLO) has announced a significant stock option grant to Caro...

Jan 10, 2025 • Major Pharmaceutical Preparations Industry Shares

Xilio Therapeutics Pioneering Anti-Cancer Therapies with Promising Clinical Data for Vilastobart and XTX301,

Advancing Cancer Treatment: Promising Data from Xilio TherapeuticsIn the rapidly evolving field of biotechnology, Xilio Therapeutics Inc. (NASDAQ: XLO) is making significant strides with its innovative approaches to can...

Dec 19, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Xilio Therapeutics Tackles Talent Acquisition and Financial Hurdles as Promising Clinical Data for Vilastobart Emerges,

Xilio Therapeutics Navigates Financial Challenges with Strategic Inducement Grants Amid Promising Clinical DevelopmentsIn a crucial endeavor to align its workforce with the evolving landscape of the biopharmaceutical in...

Dec 3, 2024 • Major Pharmaceutical Preparations Industry Shares

Promising Early Clinical Data Amid Financial Challenges A Dual Perspective on Xilio Therapeutics’ Vilastobart

The pharmaceutical landscape is frequently shaped by the dual narratives of clinical advancement and financial sustainability. A recent announcement by Xilio Therapeutics concerning initial clinical trial data for Vilas...

Nov 7, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Xilio Therapeutics: Navigating Strategic Reprioritization Amidst Financial Challenges

In a recent press release, Xilio Therapeutics Inc unveiled its strategic portfolio reprioritization plan, highlighting its focus on advancing clinical-stage programs for two promising tumor-activated therapies, XTX301 a...

Mar 28, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement

Gilead Sciences and Xilio Therapeutics Forge Exclusive Partnership to Revolutionize Cancer Treatment with Tumor-Activated IL-12 Therapy

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramFOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq:...

Mar 28, 2024 • Major Pharmaceutical Preparations Industry Licensing Agreement

Xilio Therapeutics Poised for Breakthrough in Colorectal Cancer Treatment with Promising Phase 1 Results and Initiating Phase 2 Trial

Xilio Therapeutics Announces Promising Results and Plans for Phase 2 Trial in Colorectal CancerXilio Therapeutics, a leading biotechnology company, recently declared the commencement of patient enrollment for a Phase 1...

Dec 7, 2023 Clinical Study